{"id":20501,"date":"2025-01-03T19:14:21","date_gmt":"2025-01-03T11:14:21","guid":{"rendered":"https:\/\/flcube.com\/?p=20501"},"modified":"2025-01-03T19:14:24","modified_gmt":"2025-01-03T11:14:24","slug":"shenzhen-hepalink-pharmaceuticals-to-distribute-gabapentin-in-us-under-new-agreement","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20501","title":{"rendered":"Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement"},"content":{"rendered":"\n

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399<\/a>, HKG: 9989<\/a>) has announced a product distribution agreement with Zhejiang Yongtai Technology Co., Ltd. The agreement, for which no financial details have been disclosed, appoints Hepalink as the entity responsible for the marketing, promotion, and commercialization of Yongtai\u2019s gabapentin in the United States.<\/p>\n\n\n\n

Gabapentin: Approved for Treatment of Neuropathic Pain and Epilepsy<\/strong>
Yongtai\u2019s gabapentin received approval in the US in August 2020 for the treatment of adult patients with postherpetic neuralgia and as an adjuvant treatment for partial seizure epilepsy in patients aged three and above. This antiepileptic drug\u2019s approval expands the treatment options available to patients in the US, addressing significant unmet medical needs.<\/p>\n\n\n\n

Hepalink’s Global Presence and Marketing Expertise<\/strong>
Hepalink boasts a comprehensive self-operated team, market insight system, and marketing support system across seven countries worldwide, including the United States, United Kingdom, Germany, Italy, Poland, and Spain. With a mature self-operated sales network and channels, Hepalink is well-positioned to effectively market and commercialize gabapentin in the US, leveraging its extensive experience and reach in the pharmaceutical industry.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product…<\/p>\n","protected":false},"author":1,"featured_media":20503,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[797,3029,1154,3028],"class_list":["post-20501","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hepalink-pharmaceutical","tag-hkg-9989","tag-she-002399","tag-yongtai-technology"],"yoast_head":"\nShenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product distribution agreement with Zhejiang Yongtai Technology Co., Ltd. The agreement, for which no financial details have been disclosed, appoints Hepalink as the entity responsible for the marketing, promotion, and commercialization of Yongtai\u2019s gabapentin in the United States.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20501\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement\" \/>\n<meta property=\"og:description\" content=\"China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product distribution agreement with Zhejiang Yongtai Technology Co., Ltd. The agreement, for which no financial details have been disclosed, appoints Hepalink as the entity responsible for the marketing, promotion, and commercialization of Yongtai\u2019s gabapentin in the United States.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20501\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-03T11:14:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-03T11:14:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0319.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"459\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20501#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20501\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement\",\"datePublished\":\"2025-01-03T11:14:21+00:00\",\"dateModified\":\"2025-01-03T11:14:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20501\"},\"wordCount\":194,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20501#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0319.png\",\"keywords\":[\"Hepalink Pharmaceutical\",\"HKG: 9989\",\"SHE: 002399\",\"Yongtai Technology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20501#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20501\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20501\",\"name\":\"Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20501#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20501#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0319.png\",\"datePublished\":\"2025-01-03T11:14:21+00:00\",\"dateModified\":\"2025-01-03T11:14:24+00:00\",\"description\":\"China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product distribution agreement with Zhejiang Yongtai Technology Co., Ltd. The agreement, for which no financial details have been disclosed, appoints Hepalink as the entity responsible for the marketing, promotion, and commercialization of Yongtai\u2019s gabapentin in the United States.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20501#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20501\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20501#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0319.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0319.png\",\"width\":1080,\"height\":459,\"caption\":\"Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20501#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement - Insight, China's Pharmaceutical Industry","description":"China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product distribution agreement with Zhejiang Yongtai Technology Co., Ltd. The agreement, for which no financial details have been disclosed, appoints Hepalink as the entity responsible for the marketing, promotion, and commercialization of Yongtai\u2019s gabapentin in the United States.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20501","og_locale":"en_US","og_type":"article","og_title":"Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement","og_description":"China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product distribution agreement with Zhejiang Yongtai Technology Co., Ltd. The agreement, for which no financial details have been disclosed, appoints Hepalink as the entity responsible for the marketing, promotion, and commercialization of Yongtai\u2019s gabapentin in the United States.","og_url":"https:\/\/flcube.com\/?p=20501","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-03T11:14:21+00:00","article_modified_time":"2025-01-03T11:14:24+00:00","og_image":[{"width":1080,"height":459,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0319.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20501#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20501"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement","datePublished":"2025-01-03T11:14:21+00:00","dateModified":"2025-01-03T11:14:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20501"},"wordCount":194,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=20501#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0319.png","keywords":["Hepalink Pharmaceutical","HKG: 9989","SHE: 002399","Yongtai Technology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20501#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20501","url":"https:\/\/flcube.com\/?p=20501","name":"Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=20501#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=20501#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0319.png","datePublished":"2025-01-03T11:14:21+00:00","dateModified":"2025-01-03T11:14:24+00:00","description":"China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product distribution agreement with Zhejiang Yongtai Technology Co., Ltd. The agreement, for which no financial details have been disclosed, appoints Hepalink as the entity responsible for the marketing, promotion, and commercialization of Yongtai\u2019s gabapentin in the United States.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20501#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20501"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=20501#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0319.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0319.png","width":1080,"height":459,"caption":"Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20501#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0319.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20501"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20501\/revisions"}],"predecessor-version":[{"id":20504,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20501\/revisions\/20504"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/20503"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}